'Funny' current: If heart rate slowing is not the best answer, what might be?

Cardiovascular Research

Volumn 84, Issue 1, 2009, Pages 9-10

  Gewirtz, Henry ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE; CYCLIC NUCLEOTIDE GATED CHANNEL; HCN2 POTASSIUM CHANNEL; ION CHANNEL;

DEPOLARIZATION; DIASTOLE; EDITORIAL; ENERGY METABOLISM; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART RATE; HYPERPOLARIZATION; ION CURRENT; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPERFUSION; SINUS NODE; SYSTOLE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT;

ANIMALS; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; ENERGY METABOLISM; HEART RATE; ION CHANNELS; MYOCARDIAL ISCHEMIA; RABBITS; VENTRICULAR FUNCTION, LEFT;

EID: 70349656743     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp245     Document Type: Editorial

References (12)

1. Accili EA, Proenza C, Baruscotti M, DiFrancesco D. From funny current to HCN channels: 20 years of excitation. News Physiol Sci 2002;17:32-37.
2. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 1993;55:451-467.
3. Santoro B, Grant SG, Bartsch D, Kandel ER. Interactive cloning with the SH3 domain of N-src identifies a new brain specific ion channel protein, with homology to Eag and cyclic nucleotide-gated channels. Proc Natl Acad Sci USA 1997;94:14815-14820.
4. Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature 1998; 393:587-591.
5. Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999;85:e1-e6.
6. Ceconi C, Cargnoni A, Francolini G, Parinello G, Ferrari R. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res. 2009;84: 72-82.
7. DiFrancesco D. If inhibition: a novel mechanism of action. Eur Heart J Suppl 2003;5 (Suppl G): G19-G25.
8. Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995;115:579-586.
9. Murphy E, Wong R, Steenbergen C. Signalosomes: delivering cardiopro-tective signals from GPCRs to mitochondria. Am J Physiol Heart Circ Physiol 2008;295:H920-H922.
10. Ferrari R, Williams AJ. The role of mitochondria in myocardial damage occurring on post-ischemic reperfusion. J Appl Cardiol 1986;1: 501-519.
11. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
12. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D. Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008;29:2265-2275.